SciRhom

👊 SciRhom's transition into a clinical-stage drug development organization is complete! ⬇️ The dosing of participants in the first clinical study evaluating our most advanced development program, SR-878, marks a transformational milestone and value inflection point for the company. This exciting event brings us closer than ever before to demonstrating the breakthrough potential of targeting #iRhom2 for the treatment of autoimmune diseases. The first-in-human, double-blind, placebo-controlled, single ascending dose study will assess the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of SR-878 in up to 48 healthy volunteers. The study is expected to read out in H2 2025. We are particularly excited to partner with the Department of Clinical Pharmacology at the Medical University of Vienna, Austria, whose expertise will be very valuable in establishing a solid foundation for potentially multiple subsequent studies. #trialstart #ADAM17 #TACE #autoimmune #IBD #RA #drugdiscovery

🫶 Wir freuen uns über den anhaltenden Zuspruch und die Anerkennung der Wissenschaft von SciRhom und des medizinischen Potenzials unserer #iRhom2-Strategie bei #Autoimmunkrankheiten. Wir haben sicher große Aufgaben vor uns, gehen diese aber voller Zuversicht an. Danke an alle Investoren, die für uns gestimmt haben, und schön zu sehen, dass wir in so guter Gesellschaft erwähnt werden.

Looking back at three very productive days in London full of meetings with new potential business partners and investors at the Jefferies Healthcare Conference and the Investival Showcase. Thank you to the organizers of both events for the invitation and support to make the most of our time in the British capital. Additionally, we are pleased to have earned the 3rd place in the “Series A Financing of the Year” category of the European Lifestars Award, in a year with some remarkable early-stage rounds for EU biopharma Co’s. Congratulations to our fellow Award winners. Since announcing our financing in July this year, we have made substantial progress with advancing our first #iRhom2-targeting monoclonal antibody into clinical trials. From here, our goal is to underpin the favorable safety profile of our drug candidate observed in preclinical studies, and progress swiftly toward demonstrating the clinical benefits of our novel approach in patients.

🏃♂️➡️... A busy fall continues for the SciRhom team. With #BIOEurope behind us, our Managing Director & CEO Jan Poth is heading straight to #London next week to join not one, not two, but three interesting events in close succession. Kicking things off, Jan will attend the Investival Showcase on Nov 18 and the Award Gala for the European Lifestars Awards - Celebrating Life Science Leaders, where SciRhom is nominated for Series A: Finance Raise of the Year. Finally, we will attend the Jefferies London Healthcare Conference, one of the premiere investor conferences in our industry.   Connect with us via the #Investival partnering system https://lnkd.in/edKBRYf or get in touch directly here on LinkedIn to meet next week. #LondonLifeScienceWeek #LondonHealthcareWeek #jefferieshealthcare #investival #lifestarsawards

An honor to be referenced as one example of the improving capital situation for the German biopharmaceutical industry by Handelsblatt's Maike Telgheder in yesterday's article. Congratulations to our investor Kurma Partners for achieving the first close of their new EUR 250 million Biofund IV. We always felt that innovative and solid science can attract substantial funding, and that Germany certainly has great science to offer. The topic will be further discussed in a panel including our Co-Founder and COO Jens Ruhe at Plattform Life Sciences' Finance Day. Joins us on October 24, 2024, at the #BIOCITY Leipzig to learn more about #SciRhom. Handelsblatt: https://lnkd.in/d_-DeQGF Finance Day: https://lnkd.in/d8Zb5WgM

We are proud to have been shortlisted for the 🏆 Series A: Finance Raise of the Year🏆 by European Lifestars Awards - Celebrating Life Science Leaders as one of 10 remarkable biopharma start-ups! Our EUR 63 Million Series A Financing was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners. Since announcing the transaction in July this year, we have been doubling down on advancing our first compound into clinical studies and expect to announce new developments on this end soon. Good luck to our fellow nominees. See you on November 18th at the Award Gala in London, and on the following days at the #Jefferies London Healthcare Conference. Reach out if you want to meet and learn more about the significant therapeutic potential of #iRhom2-targeting in #autoimmune disorders. #lifestarsawards #investival #JefferiesHealthcare #BIOEurope #FinanceDay #Sachs_BEF

💶 🚨 SciRhom has secured a EUR 63 Million Series A financing to accelerate iRhom2-targeting therapies in autoimmune diseases. ⬇ The financing enables us to shift gears and accelerate our novel and potentially groundbreaking therapeutic strategy toward clinical proof-of-concept and beyond to reach patients in need of better autoimmune treatments. SciRhom aims to push the boundaries in autoimmune medicine by addressing TACE/ADAM17, a master switch for various autoimmune disease-relevant signaling pathways, via iRhom2. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including HTGF | High-Tech Gründerfonds and the US-based PhiFund Ventures. We are excited to have attracted such a high-caliber international consortium of investors and appreciate our existing shareholders backing SciRhom in this crucial period of its development. In conjunction with this investment, we are excited to welcome Olivier Litzka, Peter Neubeck, Georgina Askeland, PhD, Dr. Fei Tian, and Varun Gupta to SciRhom’s Board of Directors and look forward to collaborating with them. Stay tuned and follow us here on LinkedIn to learn more about our novel approach as we progress toward initiation of a first clinical study in H2 2024. #venturecapital #financing #funding #fundingalert #SeriesA #iRhom2 #ADAM17 #TACE #autoimmune #IBD #RA #drugdiscovery #antibodyresearch #munichbiotech

📢 One big step closer to evaluating our first #iRhom2-targeting therapeutic antibody in human studies. ⬇   The approval of a clinical trial application by the Austrian regulatory authorities (BASG/AGES) for our development program SR-878 paves the way for the upcoming clinical study in the second half of 2024.   SR-878 targets iRhom2, a crucial regulator of TACE/ADAM-17, which is a master switch for various disease-relevant signaling pathways. In the upcoming study, we aim to evaluate safety in healthy volunteers and provide initial evidence of clinical activity in a second part of the study.   Stay tuned for more on SciRhom’s unique approach for breaking through the therapeutic ceiling in autoimmune diseases.   #iRhom #iRhom2 #TACE #ADAM17 #IBD #arthritis #clinicalresearch #autoimmune